Open Label Study of Treatment With LCZ696 in Patients With Severe Hypertensio
Phase 3
- Conditions
- Severe Hypertension
- Registration Number
- JPRN-jRCT2080221859
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
*Satisfy office msSBP>=180 mmHg or office msDBP>=110 mmHg at baseline.
Exclusion Criteria
*Patients show msSBP >=220 mmHg and/or msDBP >=120 mmHg.
*History of angioedema, drug-related or otherwise, as reported by the patient.
*Patients unwilling or not able to discontinue safely the use of current antihypertensive medications during the study, as required by the protocol.
*Patients have significant cardiovascular co-morbidities.
*Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.
Other protocol defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of patients with adverse events<br>Summarize the overall report of adverse event, serious adverse events including death, discontinuation due to adverse events, and notable laboratory abnormalities.
- Secondary Outcome Measures
Name Time Method